Bringing together researchers from the Hospital and the Murdoch Children’s Research Institute (MCRI), the Kidney Flagship aims to reduce the burden of genetic kidney disease on patients and their families by improving diagnosis and treatment, and the development of new targeted therapies.
The new clinical pipeline will see kidney patients with suspected genetic disease undergo a genomic test that can easily be added to routine blood tests. In many cases this test will be able to find the genetic change and identify how or why kidney disease occurred.
It will also reduce the need for unnecessary biopsies and mean less time in hospital for patients.
Following this test, researchers will be able to grow or ‘model’ the disease in a lab and aim to identify targeted treatments for the patient.
Ultimately, this could lead to the development of a drug or treatment that could improve outcomes for all kidney patients.
Posted May 2020